Charisma Hehakaya1, Jochem R N van der Voort van Zyp2, Ben G L Vanneste3, Janneke P C Grutters4, Diederick E Grobbee5, Helena M Verkooijen6, Geert W J Frederix7. 1. Division of Imaging & Oncology, University Medical Center Utrecht, The Netherlands; Julius Clinical, Zeist, The Netherlands. Electronic address: c.hehakaya@umcutrecht.nl. 2. Division of Imaging & Oncology, University Medical Center Utrecht, The Netherlands. 3. Department of Radiation Oncology, MAASTRO Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands. 4. Department for Health Evidence, Radboud Institute for Health Sciences, Radboudumc, Nijmegen, The Netherlands. 5. Julius Clinical, Zeist, The Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands; Utrecht University, The Netherlands. 6. Division of Imaging & Oncology, University Medical Center Utrecht, The Netherlands; Utrecht University, The Netherlands. 7. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands.
Abstract
BACKGROUND AND PURPOSE: 1.5 Tesla magnetic resonance imaging radiotherapy linear accelerator (MR-Linac) is gaining interest for treatment of localized prostate cancer. Clinical evidence is lacking and it therefore remains uncertain whether MR-Linac is cost-effective. An early health economic analysis was performed to calculate the necessary relative reduction in complications and the maximum price of MR-Linac (5 fractions) to be cost-effective compared to 5, 20 and 39 fractionation schedules of external beam radiotherapy (EBRT) and low-dose-rate (LDR) brachytherapy. MATERIALS AND METHODS: A state transition model was developed for men with localized prostate cancer. Complication rates such as grade ≥2 urinary, grade ≥2 bowel and sexual complications, and utilities were based on systematic literature searches. Costs were estimated from a Dutch healthcare perspective. Threshold analyses were performed to identify the thresholds of complications and costs for MR-Linac to be cost-effective, while holding other outcomes such as biochemical progression and mortality constant. One-way sensitivity analyses were performed to outline uncertainty outcomes. RESULTS: At €6460 per patient, no reductions in complications were needed to consider MR-Linac cost-effective compared to EBRT 20 and 39 fractions. Compared to EBRT 5 fractions and LDR brachytherapy, MR-Linac was found to be cost-effective when complications are relatively reduced by 54% and 66% respectively. Results are highly sensitive to the utilities of urinary, bowel and sexual complications and the probability of biochemical progression. CONCLUSIONS: MR-Linac is found to be cost-effective compared to 20 and 39 fractions EBRT at baseline. For MR-Linac to become cost-effective over 5 fractions EBRT and LDR brachytherapy, it has to reduce complications substantially or be offered at lower costs.
BACKGROUND AND PURPOSE: 1.5 Tesla magnetic resonance imaging radiotherapy linear accelerator (MR-Linac) is gaining interest for treatment of localized prostate cancer. Clinical evidence is lacking and it therefore remains uncertain whether MR-Linac is cost-effective. An early health economic analysis was performed to calculate the necessary relative reduction in complications and the maximum price of MR-Linac (5 fractions) to be cost-effective compared to 5, 20 and 39 fractionation schedules of external beam radiotherapy (EBRT) and low-dose-rate (LDR) brachytherapy. MATERIALS AND METHODS: A state transition model was developed for men with localized prostate cancer. Complication rates such as grade ≥2 urinary, grade ≥2 bowel and sexual complications, and utilities were based on systematic literature searches. Costs were estimated from a Dutch healthcare perspective. Threshold analyses were performed to identify the thresholds of complications and costs for MR-Linac to be cost-effective, while holding other outcomes such as biochemical progression and mortality constant. One-way sensitivity analyses were performed to outline uncertainty outcomes. RESULTS: At €6460 per patient, no reductions in complications were needed to consider MR-Linac cost-effective compared to EBRT 20 and 39 fractions. Compared to EBRT 5 fractions and LDR brachytherapy, MR-Linac was found to be cost-effective when complications are relatively reduced by 54% and 66% respectively. Results are highly sensitive to the utilities of urinary, bowel and sexual complications and the probability of biochemical progression. CONCLUSIONS: MR-Linac is found to be cost-effective compared to 20 and 39 fractions EBRT at baseline. For MR-Linac to become cost-effective over 5 fractions EBRT and LDR brachytherapy, it has to reduce complications substantially or be offered at lower costs.
Authors: Neil R Parikh; Mary Ann Clark; Parashar Patel; Kayla Kafka-Peterson; Lalaine Zaide; Ting Martin Ma; Michael L Steinberg; Minsong Cao; Ann C Raldow; James Lamb; Amar U Kishan Journal: Appl Radiat Oncol Date: 2021-10-05
Authors: P Hoegen; K S Zhang; E Tonndorf-Martini; F Weykamp; S Regnery; P Naumann; K Lang; J Ristau; S A Körber; C Dreher; C Buchele; C Rippke; C K Renkamp; K M Paul; L König; C Büsch; J Krisam; O Sedlaczek; H-P Schlemmer; M Niyazi; S Corradini; J Debus; S Klüter; J Hörner-Rieber Journal: Radiat Oncol Date: 2022-03-27 Impact factor: 3.481
Authors: David Cantarero-Prieto; Javier Lera; Paloma Lanza-Leon; Marina Barreda-Gutierrez; Vicente Guillem-Porta; Luis Castelo-Branco; Jose M Martin-Moreno Journal: Cancers (Basel) Date: 2022-08-24 Impact factor: 6.575
Authors: William A Hall; Amar U Kishan; Emma Hall; Himanshu Nagar; Danny Vesprini; Eric Paulson; Uulke A Van der Heide; Colleen A F Lawton; Linda G W Kerkmeijer; Alison C Tree Journal: Front Oncol Date: 2022-09-05 Impact factor: 5.738
Authors: Alessandra Castelluccia; Pierpaolo Mincarone; Maria Rosaria Tumolo; Saverio Sabina; Riccardo Colella; Antonella Bodini; Francesco Tramacere; Maurizio Portaluri; Carlo Giacomo Leo Journal: Int J Environ Res Public Health Date: 2022-08-30 Impact factor: 4.614